Summary: Roche and Hitachi High-Tech have extended their partnership for at least 10 more years, and will continue to focus on advancing lab technologies and diagnostics.
Takeaways:
- The partnership aims to enhance laboratory efficiencies, support clinical decision-making, and improve access to reliable diagnostics, with an installed base of over 84,000 diagnostic platforms globally.
- The collaboration has led to previous innovations in in-vitro diagnostic solutions, that have helped labs and healthcare systems improve patient care.
- Upcoming innovations include the cobas c 703 and cobas ISE neo analytical units, and the fully-automated cobas Mass Spec solution, designed to increase testing capacity and diagnostic accuracy.
Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration.
The renewed partnership reinforces the shared vision of Roche and Hitachi High-Tech to continue exploring new technologies that can deliver much needed efficiencies in labs, support clinicians in their decision-making, and enable people to access the rapid and reliable diagnostics, according to the companies.
“I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care,” says Palani Kumaresan, head of Roche Diagnostic Solutions. “Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients’ needs.”
Developing In-Vitro Diagnostic Solutions
Together, the companies have delivered significant innovations that paved the way for in-vitro diagnostic solutions. Their collaboration has led to innovations that have enabled labs and healthcare systems to overcome delivery challenges and get patients the care they need.
“Hitachi High-Tech and Roche have worked together to expand in the field of in-vitro diagnostics by boldly pursuing innovations. The renewal of this agreement demonstrates both companies’ commitment to the future of the global diagnostics market. We look forward to continuing to work together to further expand the utility of in-vitro diagnostics in healthcare,” says Taku Sakazume, executive officer, head of Diagnostic System Business, Hitachi High-Tech Corporation.
More than 21 billion tests are performed on Roche systems covered under this collaboration every year, a number that is expected to continue to grow with this new agreement, according to Roche.
New Tech from Roche and Hitachi
Later this year, Roche and Hitachi High-Tech plan to introduce exciting new innovations including the new analytical units cobas c 703 and cobas ISE neo for cobas pro integrated solutions, to increase potential testing capacity for labs and provide accurate and timely diagnosis for millions of patients around the world. By the end of the year, the introduction of the new cobas Mass Spec solution will mark another exciting milestone by integrating fully-automated mass spectrometry into the routine lab.
